Targeted therapy for immune dysregulation

Many degenerative diseases are linked to immune dysregulation. Dr. Hart targets immune dysregulation in degenerative diseases by using biomaterial-based immune-responsive drug delivery vehicles for delivery of immunoregulatory and disease-modifying biologics. These drug delivery vehicles are designed to eliminate challenges including rapid clearance, short half-lives and deleterious off-target effects by offering long-term release localized release of bio-instructive immunomodulatory and disease-modifying drugs that can restore tissues impaired by inflammation, disease, trauma, and aging.

Assoc. Prof. (PD) Melanie Hart, Ph.D.

Dept. of Orthopedics and Trauma Surgery Freiburg University Medical Center

Section Head, Immunomodulation and Regenerative Medicine


Habilitation at the Eberhard Karls University of Tübingen, Germany

Doctor of Philosophy (Immunology and Microbiology), Rush University Medical Center, Chicago, USA

Bachelor of Science in Applied Biology / Pre-Medicine, Ferris State University, Big Rapids, Michigan, USA


Harvard Medical School, Brigham and Women’s Hospital, Boston, USA

Tübingen University Medical Center and BG Trauma Center Tübingen, Germany


Assistant Professor at Harvard Medical School, Brigham and Women’s Hospital, Boston, USA